Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News information

Join Medicilon at Precision in Drug Discovery & Preclinical 2022 Summit

2022-01-07
|
Page View:

Join-Medicilon-at-Precision-in-Drug-Discovery-&-Preclinical-2022-Summit.png

Medicilon is excited to exhibit at Precision in Drug Discovery & Preclinical (PDDP) 2022 Summit. The European PDDP summit series is coming to Frankfurt, Germany in September 28th-29th, 2022.

ABOUT Precision in Drug Discovery & Preclinical 2022 Summit

The Precision in Drug Discovery & Preclinical event will be a unique platform for the largest bio-pharmaceutical hub in the region to network and discuss collaboration in order to achieve their discovery and scientific strategies. This gathering will showcase the progress and latest research trends that include new compounds, drug design, synthesis methods and technologies that advance the science from leaders in the pharma-biotech and academic spaces. With an innovation-focused agenda, pre-scheduled meetings between potential collaborators and a host of reliable service providers, the summit is designed to help attendees find solutions to their most pressing research challenges in 2021 and beyond.
DATE: Sep 28-29, 2022
LOCATION: Frankfurt, Germany (Europe)

Medicilon International Discovery Service Unit (IDSU)

The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies.  We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D. Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment.  In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.

Medicilon Service Scope

Medicilon-Preclinical-CRO.png

Medicilon Preclinical CRO

From its inception in 2004, Shanghai Medicilon Inc. (STAR Market stock code: 688202.SH) has been committed to providing comprehensive research and development (R&D) services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space, with the primary objective of supporting and accelerating pharmaceutical, biopharmaceutical R&D worldwide.
Our EU BD Vice President, Dr. Paul van Stralen, will be hosting the booth in the conference. Please feel free to visit him for detailed information on Medicilon’s integrated services. Join us at PDDP Europe for a two-day journey into the insightful world of drug discovery and preclinical drug development.
Relevant newsRelevant news